Shire PLC



    Today's change

    -62.00 / -1.66%

    1 year change


    As of Feb 05 2016 17:05 GMT. Data delayed by at least 15 minutes.

Search for Shire PLC and
  1. Fast FT

    January 27, 2016

    HSBC pinpoints juicy nuggets in Shire's $32bn deal

    HSBC’s pharmaceuticals analysts have been doing some trawling through SEC filings. Shares in Shire, the UK-listed but...

  2. January 15, 2016

    Shire deal demonstrates Kilsby’s M&A acumen

    Mastering the art of dealmaking has been a life-long pursuit for Susan Kilsby, the 57-year-old chairman of UK drugmaker...

Special Reports

  1. Combating Rare Diseases

    For decades, rare diseases were all but ignored by the pharmaceuticals industry. That ...
Search more Special Reports on this topic.

  1. January 11, 2016

    Shire chief’s biggest task is to make deal pay off

    Shire’s $32bn takeover of Baxalta caps the company’s transformation from a specialist in pills for teenagers with...

  2. January 11, 2016

    Shire / Baxalta: unpopular exuberance

    Shire thinks that buying Baxalta is going to make it grow faster. Not in the usual sense of offering faster-growing...

  3. January 11, 2016

    Shire agrees $32bn takeover of Baxalta

    Shire has agreed a $32bn takeover of Baxalta in a sign that the two-year-old boom in pharmaceuticals mergers and...

  4. Fast FT

    January 11, 2016

    Shire struggling at the bottom of the FTSE 100

    Is Shire over-paying for Baxalta? Shares in the UK-listed pharmaceuticals company are dropping 6 per cent as...

  5. January 11, 2016

    What $32bn deal for Baxalta means to Shire

    Shire’s agreement to buy Baxalta for $32bn marks the biggest deal in the 30-year history of the UK-listed company and...

  6. Fast FT

    January 11, 2016

    Shire up 2.5% and Baxalta up 6% on $32bn deal

    Shares in Shire and Baxalta have both jumped after the UK pharmaceutical group agreed a $32bn deal for the US...

  7. Fast FT

    January 11, 2016

    Shire bags Baxalta in deal worth $32bn

    UK pharmaceutical group Shire has agreed to buy US drug-maker Baxalta in a deal worth $32bn. The deal, which has been...

  8. January 6, 2016

    Shire deal hinges on Baxalta tax status

    Shire’s potential $32bn takeover of Baxalta is dependent on whether the UK-listed drugmaker can pay for a large part of...

  9. January 6, 2016

    Mayfieldmania does not make John Lewis a model for quoted companies

    When the great pianist Franz Liszt played, audiences swooned. It’s the same with Sir Charlie Mayfield, chief executive...

  10. January 5, 2016

    Shire/Baxalta: how to eat your words

    Many chief executives would have stuck to standard blather about the offer “substantially undervaluing” his company....

  11. January 4, 2016

    Baxalta agrees $1.6bn deal for Symphogen cancer drug tie-up

    Baxalta, the US biotech company facing renewed takeover interest from Shire, has agreed a deal worth up to $1.6bn to...

  12. December 22, 2015

    Baxalta sounds out rivals as it weighs up Shire deal

    Baxalta is sounding out potential alternatives to a takeover by Shire even as the US biotech company remains open to a...

  13. December 2, 2015

    Shire leads drug stocks sector on FTSE

    Drugmakers were the preferred sector on Wednesday as the FTSE 100 rose to a one-month high. Shire gained 2.4 per cent...

  14. November 2, 2015

    Shire / Dyax: mother of pearls

    Flemming Ornskov, the chief executive of pharma group Shire, describes his acquisition strategy as a “string of pearls”...

  15. November 2, 2015

    Shire to buy US biotech group Dyax for $5.9bn

    Shire, the acquisitive London-listed drugmaker, has struck a defensive $5.9bn deal to buy Dyax, a US biotech company...

  16. October 23, 2015

    Shire eyes alternatives amid pursuit of Baxalta

    Shire, the London-listed drugmaker, is still committed to its $30bn bid for Baxalta but the company is looking at other...

  17. October 19, 2015

    Anglo American slides on De Beers downturn fears

    Anglo American was Monday’s sharpest FTSE 100 faller on worries that its balance sheet strength will be tested by a...

  18. September 28, 2015

    Orphan drugs become big business

    Orphan drugs might target small groups of patients, but they are increasingly big business. Pharmaceutical companies,...

  19. August 21, 2015

    FTSE 100’s worst losing streak in four years

    Drugs manufacturer Shire led London’s main index lower on Friday, but its move into correction territory this week was...

  20. August 16, 2015

    Shire steps up pressure on Baxalta to break takeover deadlock

    Shire is stepping up pressure on Baxalta to open its books before the UK-listed drugmaker will consider making a higher...

  21. August 13, 2015

    US regional banks benefit in absentia

    Europeans setting out to discover the States head for New York, Boston or San Francisco. But latter-day De Tocquevilles...

  22. August 10, 2015

    Baxalta chief denounces Shire’s ‘lowball’ offer

    Baxalta has doubled down on its opposition to a $30bn hostile takeover approach from Shire, describing the...

  23. August 10, 2015

    Shire gains as biotech bubble fears ease

    Shire was among Monday’s gainers as worries eased that the drugmaker had been caught up in the biotech sector’s mergers...

  24. August 7, 2015

    Acquisitions race could lead to risky buys

    So much for a typically quiet August. Both the City of London and Wall Street were alive with corporate activity this...

  25. August 6, 2015

    Allergan says more acquisitions to come

    Brent Saunders, the frenetic dealmaker who runs Botox-maker Allergan, said there was “certainly more to come” on the...

  26. August 4, 2015

    Shire in $30bn hostile approach for Baxalta

    Shire is seeking to extend the global wave of dealmaking in the pharmaceuticals sector with a $30bn all-stock hostile...

  27. August 4, 2015

    Shire Pharmaceuticals eyes the big league with Baxalta bid

    When Flemming Ornskov took over as chief executive of Shire in 2013, the UK-listed company was viewed as a midsized...

  28. August 4, 2015

    Shire/Baxalta: merry-go-round

    Would the last American pharma company to leave, please turn out the lights? The next US drugmaker set to decamp to...

  29. August 4, 2015

    CVS Health dips on retail setback

    CVS Health shares weakened on Tuesday after the US drugstore chain warned sales growth in its retail stores had cooled...

  30. August 3, 2015

    Shire buys US eyecare business for $300m

    Shire has strengthened its move into eyecare with the $300m acquisition of a US company developing a treatment for...

  31. July 23, 2015

    Shire still on the hunt for acquisitions

    Shire, the UK-listed drugmaker, still sees opportunities for growth-boosting acquisitions despite the surge in...

  32. June 8, 2015

    Shire weighs on FTSE 100 amid bidding war fears

    Shire led the FTSE 100 lower on Monday on fears it could be drawn into a bidding war. The drugmaker dropped 2.8 per...

  33. May 19, 2015

    Circassia £275m fundraising signals revival of UK biotech sector

    When Circassia launched a £275m fundraising last week to finance two acquisitions, the Oxford-based drug developer...

  34. April 30, 2015

    Weak euro lifts European drugmakers

    Sanofi and Bayer reported strong first-quarter results and raised guidance for the full year on Thursday, as drugmakers...

  35. April 10, 2015

    FTSE 100 closes at record high, buoyed by M&A

    The FTSE 100 set a record closing high on Friday, completing a week dominated by a blockbuster deal in the energy...

  36. March 27, 2015

    Shire shines on fourth day of FTSE falls

    Shire was among the outperformers as the FTSE 100 drifted to its fourth straight decline. Drugmaker Shire gained 2.2...

  37. March 26, 2015

    Actavis rewrites ‘big pharma’ playbook

    Move over GlaxoSmithKline. There is a new pharmaceuticals giant in town. After completing its $70bn acquisition of...

  38. March 10, 2015

    Shire shines during sharp FTSE sell-off

    Shire was among the few gainers as the FTSE 100 recorded its sharpest daily fall in five months. Cowen & Co advised...

Search for Shire PLC and


Videos from FT.com that closely match this topic

  1. Lex on why tax inversions are losing their appeal...
    October 15, 2014

    Lex on why tax inversions are losing their appeal